Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration?
作者信息
Díaz Luis Antonio, Arab Juan Pablo, Leggio Lorenzo
机构信息
Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, ON, Canada.
出版信息
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):128-131. doi: 10.1080/00952990.2024.2308789. Epub 2024 Apr 9.
Abstract
摘要
相似文献
1
Granulocyte-colony stimulating factor use in alcohol-associated hepatitis: is it time to promote liver regeneration?
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):128-131. doi: 10.1080/00952990.2024.2308789. Epub 2024 Apr 9.
2
New paradigms in management of alcoholic hepatitis: a review.
Hepatol Int. 2017 May;11(3):255-267. doi: 10.1007/s12072-017-9790-5. Epub 2017 Feb 28.
3
G-CSF therapy for severe alcoholic hepatitis: targeting liver regeneration or neutrophil function?
Am J Gastroenterol. 2014 Sep;109(9):1424-6. doi: 10.1038/ajg.2014.250.
4
Liver regeneration as treatment target for severe alcoholic hepatitis.
World J Gastroenterol. 2022 Aug 28;28(32):4557-4573. doi: 10.3748/wjg.v28.i32.4557.
5
Current Therapies for Alcohol-Associated Hepatitis.
Clin Liver Dis. 2021 Aug;25(3):595-602. doi: 10.1016/j.cld.2021.03.005. Epub 2021 May 26.
6
"If a fake friend stays in your vodkabulary as a stem friend": granulocyte colony-stimulating factor promoted stem cell therapy in severe alcoholic hepatitis.
Turk J Gastroenterol. 2014 Dec;25(6):748-9. doi: 10.5152/tjg.2014.0060.
7
Insights into the Role of Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis.
Semin Liver Dis. 2021 Jan;41(1):67-78. doi: 10.1055/s-0040-1719177. Epub 2021 Feb 9.
8
G-CSF-In Patients With Severe Alcohol-Associated Hepatitis: A Real-World Experience.
Liver Int. 2025 Apr;45(4):e16137. doi: 10.1111/liv.16137. Epub 2024 Oct 28.
9
Granulocyte colony-stimulating factor plus pentoxifylline increases short-term survival in patients with severe alcoholic hepatitis: a network meta-analysis.
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):191-206. doi: 10.1080/00952990.2023.2266117. Epub 2023 Nov 27.
10
Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study.
Am J Gastroenterol. 2014 Sep;109(9):1417-23. doi: 10.1038/ajg.2014.154. Epub 2014 Jun 17.
本文引用的文献
1
Current and emerging therapies for alcohol-associated hepatitis.
Liver Res. 2023 Mar 15;7(1):35-46. doi: 10.1016/j.livres.2023.03.002. eCollection 2023 Mar.
2
Granulocyte colony-stimulating factor plus pentoxifylline increases short-term survival in patients with severe alcoholic hepatitis: a network meta-analysis.
Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):191-206. doi: 10.1080/00952990.2023.2266117. Epub 2023 Nov 27.
3
Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
J Hepatol. 2024 Mar;80(3):409-418. doi: 10.1016/j.jhep.2023.11.006. Epub 2023 Nov 21.
4
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease.
Hepatology. 2025 Jul 1;82(1):254-271. doi: 10.1097/HEP.0000000000000645. Epub 2025 Jun 19.
5
Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial.
JAMA. 2023 May 9;329(18):1558-1566. doi: 10.1001/jama.2023.4902.
6
Liver transplantation for alcohol-associated liver disease: A call for national standards of best practices to monitor and bridge disparities in access and outcomes.
Am J Transplant. 2023 Aug;23(8):1097-1101. doi: 10.1016/j.ajt.2023.03.026. Epub 2023 Apr 5.
7
Adding Inflammatory Markers and Refining National Institute on Alcohol Abuse and Alcoholism Criteria Improve Diagnostic Accuracy for Alcohol-associated Hepatitis.
Clin Gastroenterol Hepatol. 2023 Nov;21(12):3080-3088.e9. doi: 10.1016/j.cgh.2023.03.023. Epub 2023 Mar 31.
8
Alcohol-Associated Hepatitis.
N Engl J Med. 2022 Dec 29;387(26):2436-2448. doi: 10.1056/NEJMra2207599.
9
Public Health Measures and Prevention of Alcohol-Associated Liver Disease.
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1480-1491. doi: 10.1016/j.jceh.2022.05.005. Epub 2022 May 31.
10
A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis.
EClinicalMedicine. 2022 Oct 12;54:101689. doi: 10.1016/j.eclinm.2022.101689. eCollection 2022 Dec.
Zotero 插件